TLX - Telix Pharmaceuticals

[Dona Ferentes]

pushed through $30

Telix Pharmaceuticals has forecast full-year 2025 revenue of $1.18bn to $1.23bn, driven by strong sales of its prostate cancer imaging agent.

 

[Miner]

@Miner, don't know mate. All I know with certainty is .. it's getting closer, haha.
This one may never get cheap enough.

@finicky
Looks like your predicted crash happened today and more on Monday
On December 1, it was around $24, and today, it shot up to $30.
It is always a challenging game. I bought it for $2 and sold it for $6 or so (I have to check the dates and transactions), thinking, OMG, it was too much. I would have retired by holding it just a bit more. We can look back and find our sure-win Lotto numbers but never pick up the actual numbers before the game.
This report highlights some real game changers through Phase 2 and 3 in 2025. I am guessing and not believing myself that 2025 will raise the bar for TLX to a higher level

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02915507-3A662150